EHD1 and cancer: We have provided evidence that CD133 expression is positively associated with EGFR-TKI resistance and high levels of EHD1 in patients, and NF-κB/miR-590/EHD1 acts as a novel mechanism, promoting EGFR-TKI resistance via enhanced cancer CSC-like properties in vitro and in vivo.